Lanreotide Activity and Synergy in Combination with Targeted Agents in Gastrointestinal Neuroendocrine Tumors (GI-NET): Ex Vivo Analysis of Programmed Cell Death (EVA/PCD) in GI-NETs Isolated from Patients with Advanced Disease
#741
Introduction: Somatostatin receptor ligation can affect vascular signals, induce apoptosis and provide objective responses in some GI-NET patients.
Aim(s): We applied EVA/PCD (Nagourney. Curr Treat Rep Oncol 2006) to examine effects of the somatostatin analogue Lanreotide (Lan) on tumor specimens isolated from 35 GI-NET patients.
Materials and methods: Microspheroids were isolated from surgical specimens and exposed to Lan alone and in combination with Everolimus (Ever), Pazaponib (Paz), Sunitinib (Sun), LX1032 and Bevacizumab (Bev). Drug-induced cell death was measured by delayed loss-of-membrane-integrity and ATP-content. Lethal concentrations (LC50s) were interpolated from dose response curves. Synergy was analyzed by median effect.
Conference: 10th Annual ENETSConcerence (2013)
Presenting Author:
Authors: Nagourney R, Evans S, Woltering E, Gomez-Panzani E,
Keywords: combination therapy,
To read the full abstract, please log into your ENETS Member account.